EHA 2016 | Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses the efficacy and safety of the CD19 targeted chimeric antigen receptor (CAR) T-cells in relapsed B-cell acute lymphoblastic leukemia (ALL) adult patients. CAR T-cells are the patient’s own T-cells which have been genetically engineered to express a chimeric antigen receptors that’s engineered to target a specific tumor antigens, in this case CD19. A Phase I clinical trial has been conducted on 51 subjects, and has had positive results. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up